Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.45 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.45 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524476 | 1.00 | NPC1 (0.59) | NPC1RAB9AL3MBTL1ACESMN1; SMN2 | |
| SCHEMBL4513851 | 1.00 | NPC1 (0.59) | NPC1RAB9AL3MBTL1ACESMN1; SMN2 | |
| SCHEMBL13711930 | 0.88 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACESMN1; SMN2 | |
| SCHEMBL24582713 | 0.87 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL3208272 | 0.87 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL1000224 | 0.87 | NPC1 (0.54) | NPC1RAB9AL3MBTL1ACE | |
| SCHEMBL13711928 | 0.86 | NPC1 (0.52) | NPC1RAB9AL3MBTL1ACESMN1; SMN2 | |
| SCHEMBL13711929 | 0.85 | NPC1 (0.51) | NPC1RAB9AL3MBTL1ACESMN1; SMN2 | |
| SCHEMBL3600152 | 0.83 | SMN1; SMN2 (0.53) | NPC1RAB9AL3MBTL1ACESMN1; SMN2 | |
| SCHEMBL3600148 | 0.83 | SMN1; SMN2 (0.53) | NPC1RAB9AL3MBTL1ACESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
| EP-1836192-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | Universita' Degli Studi di Siena (IT) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006072608-A2 | ARYL PIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | UNIVERSITÁ DEGLI STUDI DI SIENA (IT) | 2006-07-13 | — | — | WO | disclosed |
| US-7053057-B2 | A carbamate and amide compound containing piperidine, tetrahydroquinoline or tetrahydroisoquinoline ring; enzyme inhibitor | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-05-30 | — | — | US | disclosed |
| US-20020061853-A1 | Caspase inhibtors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2002-05-23 | — | — | US | disclosed |
| EP-0595610-B1 | Benzo-fused lactams | SQUIBB & SONS INC (US) | 1997-05-07 | — | — | EP | disclosed |
| US-5504080-A | Benzo-fused lactams | BRISTOL-MYERS SQUIBB CO. (US) | 1996-04-02 | — | — | US | disclosed |
| EP-0595610-A1 | Benzo-fused lactams | E.R. SQUIBB & SONS, INC. (US) | 1994-05-04 | — | — | EP | disclosed |
| US-4461896-A | 1-[Acylthio) and (mercapto)-1-oxoalkyl]-1,2,3,4-tetrahydroquinoline-2-carboxylic acids | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1984-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020061853-A1 | Caspase inhibtors and uses thereof | CASP2, CASP1, CASP3 | NPC1 3026/4885RAB9A 3242/4885L3MBTL1 1454/4885 |
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | NPC1 3391/4885RAB9A 2613/4885L3MBTL1 3890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.